Economics of low-molecular weight heparins

American Journal of Managed Care

Volumn 6, Issue 20 SUPPL., 2000, Pages

  Rutschmann, O T ^a   Matchar, D B ^a  

^a DUKE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DANAPAROID; ENOXAPARIN; HEPARIN; LOW MOLECULAR WEIGHT HEPARIN; NADROPARIN; TINZAPARIN; WARFARIN;

CLINICAL TRIAL; COST BENEFIT ANALYSIS; COST EFFECTIVENESS ANALYSIS; DEEP VEIN THROMBOSIS; DRUG COST; DRUG EFFICACY; DRUG SAFETY; ECONOMIC EVALUATION; HEALTH CARE COST; HEART MUSCLE ISCHEMIA; HOSPITAL CARE; HUMAN; LENGTH OF STAY; MANAGED CARE; META ANALYSIS; PATIENT CARE; PRIORITY JOURNAL; RECURRENT DISEASE; REVIEW; THROMBOEMBOLISM; TREATMENT OUTCOME;

ANTIFIBRINOLYTIC AGENTS; COST OF ILLNESS; DECISION SUPPORT TECHNIQUES; DRUG COSTS; EDUCATION, MEDICAL, CONTINUING; EDUCATION, PHARMACY, CONTINUING; HEPARIN, LOW-MOLECULAR-WEIGHT; HOSPITAL COSTS; HUMANS; MANAGED CARE PROGRAMS; UNITED STATES; VENOUS THROMBOSIS;

EID: 0033665705     PISSN: 10880224     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (51)

1. Current and potential uses of low molecular weight heparin: A review and an economic analysis
2. Management of deep vein thrombosis and pulmonary embolism. A statement for healthcare professionals. Council on Thrombosis (in consultation with the council on cardiovascular radiology), American Heart Association
3. Low molecular weight heparins in the outpatient management of venous thromboembolism
4. Anticoagulant drugs in the treatment of pulmonary embolism: A controlled trial
5. Treatment of deep venous thrombosis with low-molecular-weight heparins. A meta-analysis
6. Low-molecular-weight heparins and unfractioned heparin in the treatment of patients with acute venous thromboembolism: Results of a meta-analysis
7. Low-molecular-weight heparins compared with unfractioned heparin for treatment of acute deep venous thrombosis. A meta-analysis of randomized, controlled trials
8. Fixed dose subcutaneous low molecular weight heparins versus adjusted dose unfractioned heparin for venous thromboembolism
9. Proceedings of the American College of Chest Physicians 5th Consensus on Antithrombotic Therapy. 1998
10. Home treatment for deep venous thrombosis with low-molecular-weight heparin
11. Comparison of low-molecular-weight heparin, administered primarily at home, with unfractionated heparin, administered in hospital, and subcutaneous heparin, administered at home for deep-vein thrombosis
12. Outpatient therapy with low-molecular-weight heparins: New perspectives for treatment of deep vein thrombosis
13. Patient outcomes and cost analysis associated with an outpatient deep venous thrombosis treatment program
14. Treatment of venous thrombosis with intravenous unfractionated heparin administered in the hospital as compared with subcutaneous low-molecular-weight heparin administered at home. The Tasman Study Group
15. A comparison of low-molecular-weight heparin administered primarily at home with unfractionated heparin administered in the hospital for proximal deep-vein thrombosis
16. Economic evaluation of outpatient treatment with low-molecular-weight heparin for proximal vein thrombosis
17. Clinical outcome and cost of hospital vs home treatment of proximal deep vein thrombosis with a low-molecular-weight heparin: The Vascular Midi-Pyrenees study
18. Subcutaneous low-molecular-weight heparin compared with continuous intravenous heparin in the treatment of proximal-vein thrombosis
19. Treatment of proximal vein thrombosis with subcutaneous low-molecular-weight heparin vs intravenous heparin. An economic perspective
20. Replacing inpatient care by outpatient care in the treatment of deep venous thrombosis - An economic evaluation. TASMAN study group
21. Cost effectiveness and ease of administration of low molecular weight heparin in deep vein thrombosis
22. An outpatient program to treat deep venous thrombosis with low-molecular-weight heparin
23. Pharmacy-managed program for home treatment of deep vein thrombosis with enoxaparin
24. Use of low molecular weight heparin (dalteparin), once daily, for the treatment of deep vein thrombosis. A feasibility and health economic study in an outpatient setting. Swedish Venous Thrombosis Dalteparin Trial Group
25. Low-molecular-weight heparins compared with unfractionated heparin for treatment of acute deep venous thrombosis. A cost-effectiveness analysis
26. Cost-effectiveness of low-molecular-weight heparin and unfractionated heparin in treatment of deep vein thrombosis
27. Cost-effectiveness of low-molecular-weight heparin in the treatment of proximal deep vein thrombosis
28. Comparison of low-molecular-weight heparin with unfractionated heparin acutely and with placebo for 6 weeks in the management of unstable coronary artery disease
29. A comparison of low-molecular-weight heparin with unfractionated heparin for unstable coronary artery disease. Efficacy and Safety of Subcutaneous Enoxaparin in Non-Q-Qave Coronary Events Study Group
30. Enoxaparin prevents death and cardiac ischemic events in unstable angina/non-Q-wave myocardial infarction. Results of the Thrombolysis in Myocardial Infaction (TIMI) 11B trial
31. Comparison of two treatment durations (6 days and 14 days) of a low-molecular-weight heparin with a 6-day treatment of unfractionated heparin in the initial management of unstable angina or non-Q-wave myocardial infarction. FRAXIS
32. Low molecular weight heparin versus regular heparin or aspirin in the treatment of unstable angina and silent ischemia
33. Economic assessment of low-molecular-weight heparin (enoxaparin) versus unfractionated heparin in acute coronary syndrome patients. Results from the ESSENCE randomized trial
34. Will the use of low-molecular-weight heparin (enoxaparin) in patients with acute coronary syndrome save costs in Canada?
35. Cost effectiveness of low-molecular weight heparin versus warfarin following hip replacement surgery
36. A pharmacoeconomic assessment of enoxaparin and warfarin as prophylaxis for deep vein thrombosis in patients undergoing knee replacement surgery
37. Prevention of deep vein thrombosis after elective hip surgery: A randomized trial comparing low molecular weight heparin with standard unfractionated heparin
38. Pharmacoeconomic model of enoxaparin versus heparin for prevention of deep vein thrombosis after total hip replacement
39. Subcutaneous low-molecular-weight heparin vs warfarin for prophylaxis of deep vein thrombosis after hip or knee implantation. An economic perspective
40. Efficacy and cost of low-molecular-weight heparin compared with standard heparin for the prevention of deep vein thrombosis after total hip arthroplasty
41. Cost-effectiveness of enoxaparin vs low-dose warfarin in the prevention of deep-vein thrombosis after total hip replacement surgery
42. Cost-effectiveness of enoxaparin versus warfarin prophylaxis against deep-vein thrombosis after total hip replacement
43. Cost effectiveness of danaparoid compared with enoxaparin as deep vein thrombosis prophylaxis after hip replacement surgery
44. Economic analysis of low-dose heparin vs the low-molecular-weight heparin enoxaparin for prevention of venous thromboembolism after colorectal surgery
45. Cost-effectiveness analysis of deep vein thrombosis prophylaxis in internal medicine patients
46. Assessment of outpatient treatment of deep-vein thrombosis with low-molecular-weight heparin
47. Outpatient treatment of deep vein thrombosis: Translating clinical trials into practice
48. Low-molecular-weight heparin in outpatient treatment of DVT
49. Criteria for outpatient management of proximal lower extremity deep venous thrombosis
50. Unfractionated heparin and low-molecular-weight heparin in acute coronary syndrome without ST elevation: A meta-analysis
51. Do better treatments save money?